Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL

被引:13
作者
Canby-Hagino, Edith
Hernandez, Javier
Brand, Timothy C.
Troyer, Dean A.
Higgons, Betsy
Ankerst, Donna Pauler
Thompson, Ian M.
Leach, Robin J.
Parekh, Dipen J.
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA
[3] Brooke Army Med Ctr, Div Urol, San Antonio, TX USA
关键词
D O I
10.1016/j.urology.2007.06.1105
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Family history has been identified as a risk factor for prostate cancer. We assessed the risk of prostate cancer in men with a positive family history (at least one first-degree or second-degree relative), normal digital rectal examination (DRE) and a serum prostate-specific antigen (PSA) level of 4.0 ng/mL. METHODS A total of 87 volunteers from the San Antonio Center of biomarkers of risk for prostate cancer study enrolled in a prospective study to assess the prevalence of prostate cancer in men with a family history of prostate cancer, normal DRE findings, and a serum PSA level of 4.0 ng/mL or less. All subjects underwent transrectal ultrasound-guided prostate biopsy. RESULTS Prostate cancer was diagnosed in 22 (25.3%) of the 87 participants. The PSA values were significantly greater statistically in the men with prostate cancer (median 2.1 ng/mL) than in the men without prostate cancer (median 1.2 ng/mL, P = 0.01), and the odds of prostate cancer nearly doubled for a doubling of the PSA level within this interval (odds ratio 1.97, P = 0.02). No statistically significant difference was found in age, race, or number and type of affected relatives in men with and without prostate cancer. CONCLUSIONS The results of our study have demonstrated a high frequency of prostate cancer in men with a positive family history but normal DRE findings and a PSA level of 4.0 ng/mL or less. These prospectively collected data raise an important consideration regarding lowering the PSA cutoff values for offering biopsy in patients with a positive family history and normal DRE findings.
引用
收藏
页码:748 / 752
页数:5
相关论文
共 33 条
[1]   Preoperative PSA and progression-free survival after radical prostatectomy for stage T1c disease [J].
Antenor, JAV ;
Roehl, KA ;
Eggener, SE ;
Kundu, SD ;
Han, M ;
Catalona, WJ .
UROLOGY, 2005, 66 (01) :156-160
[2]   Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men [J].
Balic, I ;
Graham, ST ;
Troyer, DA ;
Higgins, BA ;
Pollock, BH ;
Johnson-Pais, TL ;
Thompson, IM ;
Leach, RJ .
JOURNAL OF UROLOGY, 2002, 168 (05) :2245-2248
[3]   Prostate cancer early detection practices among men with a family history of disease [J].
Bock, CH ;
Peyser, PA ;
Gruber, SB ;
Bonnell, SE ;
Tedesco, KL ;
Cooney, KA .
UROLOGY, 2003, 62 (03) :470-475
[4]   Hereditary prostate cancer: Clinical aspects [J].
Bratt, O .
JOURNAL OF UROLOGY, 2002, 168 (03) :906-913
[5]   Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis [J].
Bruner, DW ;
Moore, D ;
Parlanti, A ;
Dorgan, J ;
Engstrom, P .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (05) :797-803
[6]  
Cerhan JR, 1999, CANCER EPIDEM BIOMAR, V8, P53
[7]  
Durham John, 2003, N Z Med J, V116, pU476
[8]   PROSTATE-CANCER RISK IN US BLACKS AND WHITES WITH A FAMILY HISTORY OF CANCER [J].
HAYES, RB ;
LIFF, JM ;
POTTERN, LM ;
GREENBERG, RS ;
SCHOENBERG, JB ;
SCHWARTZ, AG ;
SWANSON, GM ;
SILVERMAN, DT ;
BROWN, LM ;
HOOVER, RN ;
FRAUMENI, JF .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (03) :361-364
[9]   Association between an eestrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men [J].
Hernández, J ;
Balic, I ;
Johnson-Pais, TL ;
Higgins, BA ;
Torkko, KC ;
Thompson, IM ;
Leach, RJ .
JOURNAL OF UROLOGY, 2006, 175 (02) :523-527
[10]   Prognostic markers under watchful waiting and radical prostatectomy [J].
Holmberg, Lars ;
Bill-Axelson, Anna ;
Garmo, Hans ;
Palmgren, Juni ;
Norlen, Bo Johan ;
Adami, Hans Olov ;
Johansson, Jan Erik .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 20 (04) :845-+